Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 6:12 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1345–1368 of 7,632 matching trials from the live ClinicalTrials.gov search.

Filters: Jacksonville, Florida Clear all

Conditions: Diabetic Gastroparesis, Idiopathic Gastroparesis
Interventions: NG101, Placebo; Drug
Lead sponsor: Neurogastrx, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 83
States / cities: Dothan, Alabama • Foley, Alabama • Mobile, Alabama + 69 more

Conditions: Arthralgia, Breast Cancer, Hot Flashes, Musculoskeletal Complications, Sexual Dysfunction
Interventions: testosterone, placebo; Drug · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older · Female only
Enrollment: 227 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 528
States / cities: Anchorage, Alaska • Hot Springs, Arkansas • Auburn, California + 331 more

Conditions: Colorectal Cancer
Interventions: irinotecan, fluorouracil, leucovorin calcium, oxaliplatin; Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 1,691 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2004
U.S. locations: 430
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 261 more

Conditions: Acute Migraine
Interventions: Zavegepant (BHV-3500); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 974 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 67
States / cities: Huntsville, Alabama • Mobile, Alabama • Tucson, Arizona + 62 more

Conditions: Lung Cancer
Interventions: Nivolumab, Ipilimumab, Placebo; Biological · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 907 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 28
States / cities: Sacramento, California • New Haven, Connecticut • Fort Myers, Florida + 23 more

Conditions: Brain Edema, Brain Tumor
Interventions: hCRF, placebo hCRF; Drug
Lead sponsor: Celtic Pharma Development Services; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 27
States / cities: Phoenix, Arizona • Fresno, California • Newport Beach, California + 22 more

Conditions: Ischemic Attack, Transient
Interventions: Clopidogrel, placebo; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 4,881 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 147
States / cities: Chandler, Arizona • Tucson, Arizona • Carmichael, California + 95 more

Conditions: HIV
Interventions: HIV positive subjects, Non-infected control subjects; Other
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 65 Years
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2028
U.S. locations: 2
States / cities: Gainesville, Florida • Jacksonville, Florida

Conditions: Menopause Syndrome, Menopause, Hot Flashes
Interventions: NOE-115; Drug
Lead sponsor: Noema Pharma AG; Industry
Eligibility: 45 Years to 60 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 5
States / cities: San Diego, California • Jacksonville, Florida • Atlanta, Georgia + 2 more

Conditions: Coronary Artery Disease, Ischemic Heart Disease, Non ST Segment Elevation Myocardial Infarction
Interventions: Orbital Atherectomy, Balloon; Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years and older
Enrollment: 2,005 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 104
States / cities: Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 83 more

Conditions: Chronic Low Back Pain
Interventions: PF-06372865, Placebo, Naproxen; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 302 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 46
States / cities: Mesa, Arizona • Phoenix, Arizona • Anaheim, California + 36 more

Conditions: Non Small Cell Lung Cancer
Interventions: Sacituzumab tirumotecan, Pembrolizumab, Cisplatin, Pemetrexed, Gemcitabine, Carboplatin, Paclitaxel, Rescue medication; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 780 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2034
U.S. locations: 51
States / cities: Little Rock, Arkansas • Springdale, Arkansas • Beverly Hills, California + 41 more

Conditions: Early Stage Triple-Negative Breast Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Cervical Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Endometrial Carcinoma, Metastatic Esophageal Carcinoma, Metastatic Liver Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Skin Neoplasm, Metastatic Malignant Solid Neoplasm, Resectable Lung Non-Small Cell Carcinoma, Early Stage Lung Non-Small Cell Carcinoma, Resectable Malignant Solid Neoplasm, Resectable Triple-Negative Breast Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Cervical Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Recurrent Cervical Carcinoma, Recurrent Colorectal Carcinoma, Recurrent Endometrial Carcinoma, Recurrent Esophageal Carcinoma, Recurrent Liver Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Recurrent Malignant Skin Neoplasm, Recurrent Malignant Solid Neoplasm
Interventions: Biospecimen Collection, Tissue Collection; Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 324 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 3
States / cities: Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: Hypertension
Interventions: Azilsartan medoxomil and olmesartan, Olmesartan, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 1,275 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 80
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mesa, Arizona + 77 more

Conditions: Attention-deficit/Hyperactivity Disorder
Interventions: Lisdexamfetamine dimesylate, Methylphenidate Hydrochloride, Placebo; Drug
Lead sponsor: Shire; Industry
Eligibility: 13 Years to 17 Years
Enrollment: 549 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 81
States / cities: Dothan, Alabama • Tucson, Arizona • Little Rock, Arkansas + 68 more

Conditions: Acute Coronary Syndrome
Interventions: Apolipoprotein A-I [human] (apoA-I), Placebo; Biological · Other
Lead sponsor: CSL Behring; Industry
Eligibility: 18 Years and older
Enrollment: 18,226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 202
States / cities: Alexander City, Alabama • Birmingham, Alabama • Huntsville, Alabama + 175 more

Conditions: Chronic Pain, Osteoarthritis, Hip, Osteoarthritis, Knee
Interventions: NSAID, Tanezumab 2.5 mg, Tanezumab 5 mg; Drug · Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 3,021 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 299
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 187 more

Conditions: Ankle Foot Orthosis (AFO), Stroke Patients, Post-Stroke Hemiparesis
Interventions: Pre-fabricated (PF) ankle-foot orthosis (AFO), Carbon-strut (CS) ankle-foot orthosis (AFO), Multifunctional articulating (MA) ankle-foot orthosis (AFO); Device
Lead sponsor: University of Texas at Austin; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 4
States / cities: Downey, California • Jacksonville, Florida • Charleston, South Carolina + 1 more

Conditions: Low Back Pain
Interventions: Hydrocodone ER, Placebo; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 625 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 87
States / cities: Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 71 more

Conditions: HIV Infections
Interventions: Indinavir sulfate, Ritonavir, Nevirapine, Lamivudine, Stavudine, Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 2 Years to 17 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2001
U.S. locations: 58
States / cities: Birmingham, Alabama • La Jolla, California • Long Beach, California + 39 more

Conditions: ADHD
Interventions: Solriamfetol; Drug
Lead sponsor: Axsome Therapeutics, Inc.; Industry
Eligibility: 6 Years to 18 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 10
States / cities: Dothan, Alabama • Little Rock, Arkansas • Coral Gables, Florida + 7 more

Conditions: HIV/AIDS, Sexually Transmitted Infections
Interventions: RESPECT-2 Counseling; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 5,012 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 9
States / cities: Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 6 more

Conditions: Alzheimer Disease
Interventions: Donanemab, Placebo, LY3202626; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 60 Years to 85 Years
Enrollment: 272 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 56
States / cities: Phoenix, Arizona • Sun City, Arizona • Fullerton, California + 47 more

Conditions: Prostate Cancer
Interventions: Immunotherapy with allogeneic prostate vaccine, Chemotherapy (Taxotere and prednisone); Biological · Drug
Lead sponsor: Cell Genesys; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 626 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 83
States / cities: Alabaster, Alabama • Anchorage, Alaska • Glendale, Arizona + 71 more

Search by objective public record fields.

A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants With Symptomatic Diabetic or Idiopathic Gastroparesis

Testosterone in Treating Postmenopausal Patients With Arthralgia Caused by Adjuvant Aromatase Inhibitor Treatment

Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer

Long-term Safety Study of BHV-3500 (Zavegepant*) for the Acute Treatment of Migraine

An Investigational Immuno-therapy Study of Nivolumab, or Nivolumab in Combination With Ipilimumab, or Placebo in Patients With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based Chemotherapy

XERECEPT® (hCRF) for Patients Requiring Dexamethasone to Treat Edema Associated With Brain Tumors

Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial

Selection of a Protective T Cell-based HIV-1/FIV Vaccine

A Study of NOE-115 in Women With Vasomotor Symptoms Due to Menopause

Evaluation of Treatment Strategies for Severe CaLcIfic Coronary Arteries: Orbital Atherectomy vs. Conventional Angioplasty Technique Prior to Implantation of Drug-Eluting StEnts: The ECLIPSE Trial

PF-06372865 In Subjects With Chronic Low Back Pain

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform

Efficacy and Safety of Azilsartan Medoxomil in Participants With Essential Hypertension

Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder

Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome

Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee

AFO Prescription to Optimize Post-Stroke Function

Efficacy and Safety of Hydrocodone Bitartrate Extended-Release Tablets for Moderate to Severe Chronic Low Back Pain

Comparison of New Anti-HIV Drug Combinations in HIV-Infected Children Who Have Taken Anti-HIV Drugs

An Open-Label Study to Assess the Long-Term Safety of Solriamfetol in Children and Adolescents With ADHD

HIV Rapid Testing & Counseling in Sexually Transmitted Disease (STD) Clinics in the U.S.

A Study of LY3002813 in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ)

GVAX® Vaccine for Prostate Cancer vs Docetaxel & Prednisone in Patients With Metastatic Hormone-Refractory Prostate Cancer